Author

T. Wattanakul

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 1 Pathology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:benchmarking· 1 Approach:deep learning· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1 Approach:transformer / foundation model· 1

Frequent Co-Authors

E. Chatelain· 2 shared F. Escudie· 2 shared I. Scandale· 2 shared J. Tarning· 2 shared P. Chotsiri· 2 shared A. Nougairede· 1 shared A. Sole· 1 shared B. Weynand· 1 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPathology

E. Chatelain

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Named Entity Recognition of Pharmacokinetic parameters in the scientific literature

F. G. Hernandez, Q. Nguyen, V. C. Smith, J. A. Cordero, M. R. Ballester, M. Duran, A. Sole, P. Chotsiri, T. Wattanakul, G. Mundin, W. Lilaonitkul, J. F. Standing, F. Kloprogge

This paper introduces a novel corpus and language models for Named Entity Recognition of pharmacokinetic parameters in scientific literature, achieving high accuracy with BioBERT.

bioRxiv · Feb 12, 2024 · PreprintPharmacology & Toxicology

Pre-clinical evaluation of antiviral activity of nitazoxanide against Sars-CoV-2

J.-S. Driouich, M. Cochin, F. Touret, P.-R. Petit, M. Gilles, G. Moureau, K. Barthelemy, C. Laprie, T. Wattanakul, P. Chotsiri, R. M. Hoglund, J. Tarning, F. Escudie, I. Scandale, E. Chatelain, , A. Nougairede

This study evaluates nitazoxanide's antiviral activity against SARS-CoV-2 in vitro and in vivo, finding that its standard dosage is ineffective due to insufficient drug concentration in target organs.

bioRxiv · Dec 17, 2021Pathology

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern

R. Abdelnabi, C. S.-Y. Foo, D. Jochmans, L. Vangeel, S. De Jonghe, P. Augustijns, R. Mols, B. Weynand, T. Wattanakul, R. Hoglund, J. Tarning, C. Mowbray, P. Sjo, F. Escudie, I. Scandale, , J. Neyts

PF-07321332, an oral protease inhibitor, effectively protects Syrian hamsters against SARS-CoV-2 variants of concern, including beta and delta, by preventing infection and transmission.

bioRxiv · Nov 4, 2021Microbiology